Prospects for the manufacture of red cells for transfusion.

摘要: Whilst red cell transfusion is a well established cellular therapy, the problems of insufficiency supply, transmitted infections and requirement for immunological matching persist. The possibility generating large numbers O Rh D negative cells at Good Manufacturing Practice grade as route to circumvent these issues therefore an attractive proposition. Significant erythrocytes can be generated from somatic haematopoietic stem cells, but it seems unlikely that provide sufficient volumes scale manufacture. However, human embryonic (hESC) and, potentially, induced pluripotent (iPSC), may this objective. Red goal cell-derived therapeutics because well-characterised single suspension lacks nucleated has low expression leucocyte antigen molecules, many challenges remain in translating therapy clinic.